PHAT shares fall about 7% after Leerink starts Market Perform
Phathom Pharmaceuticals (PHAT) shares slid about 7% after Leerink Partners opened coverage with a Market Perform rating and a $10 price target, citing limited near-term upside from a crowded, price-sensitive market for its acid-reflux drug.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.